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epression After
yocardial Infarction
nraveling the Mystery of
oor Cardiovascular Prognosis
nd Role of Beta-Blocker Therapy*
oland von Känel, MD,†‡
tefan Begré, MD†
erne, Switzerland
epression is now a recognized independent risk factor of
oronary artery disease. Post-myocardial infarction (MI)
atients with a clinician-diagnosed depressive disorder or
elf-reported depressive symptoms carry a 2.0- to 2.5-fold
ncreased relative risk of new cardiovascular events and
ardiac mortality (1). Approximately 40% of post-MI pa-
ients have either major or minor depression (2). Given this
nequivocal importance of depression to clinical cardiology,
reviously published results of the ENRICHD (Enhancing
ecovery in Coronary Heart Disease) trial were disappoint-
ng news. In the ENRICHD trial, treatment of depression
n post-MI patients with cognitive behavioral therapy did
ot improve cardiac event-free survival and overall mortality
ompared with usual medical care (3). Although non-
andomized treatment with selective serotonin reuptake
nhibitors (SSRIs) significantly improved outcome in the
NRICHD trial, this could essentially relate to intrinsic
harmacologic properties of SSRIs causing, for example,
estoration of subtle platelet hyperactivity in the de-
ressed (3).
See pages 2204 and 2209
Clearly, before another clinical trial of depression treat-
ent is initiated in post-MI populations, we need more
nformation on the “cardiotoxic” subtypes of depression.
his is exactly what de Jonge et al. (4) achieved with their
roundbreaking investigation presented in this issue of the
ournal. They studied a sample of 468 post-MI patients,
redominantly men in their early 60s, of whom almost 25%
ad a recurrent fatal or non-fatal cardiovascular event,
efined as cardiovascular mortality, and cardiac-related re-
dmissions during an average follow-up of 2.5 years. Pa-
ients who developed depression for the very first time after
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of General Internal Medicine, Division of Psychosomatic
edicine, University Hospital Berne, Berne, Switzerland; and ‡Cardiovascular
revention and Rehabilitation, Psychocardiology Unit, Swiss Cardiovascular Center,s
niversity Hospital Berne, Berne, Switzerland. Dr. von Känel has recently received
unding from Pfizer Inc., Switzerland.heir MI (“incident post-MI depression”) showed the high-
st risk of a new cardiovascular event. Strikingly, this risk
as significantly lower and similar in patients who were
epressed before the onset of MI (“non-incident post-MI
epression”) and in patients without post-MI depression.
hese findings held when controlled for MI severity,
ersonality factors, and socioeconomic status. One strength
f their protocol is that they performed a structured clinical
nterview to formally diagnose depression. This sound
ethodology supports another recent study showing that
epressive symptom level at the time of, but not before,
ospitalization predicted all-cause mortality at 5-year
ollow-up, even after adjustment for other prognostic indi-
ators (5). Most remarkably, these findings suggest that
epression onset before MI may not be causally linked with
I, supporting the most recent notion that this link is
artially due to a shared genetic vulnerability (6).
It is of utmost clinical importance to find treatment
ptions for incident post-MI depression. In order to
ecrease cardiac risk, such treatments must also favorably
ffect alterations in cardiovascular biology accompanying
epression. The ENRICHD trial suggests this treatment
ay not be standard cognitive behavioral therapy used to
reat depression in the general population (3). Also, in
he SADHART (Sertraline Antidepressant Heart Attack
rial), sertraline did not reduce depressed mood more
han placebo in patients with onset of a major depressive
pisode after they entered the hospital because of an acute
oronary syndrome (7). de Jonge et al. (4) encourage
ellow researchers to adopt a more individually tailored
pproach to treatment. They remind us that current
tandard diagnostic manuals of psychiatric disorders di-
gnose depression based on the sum of depressive symp-
oms adding up to a syndromal diagnosis of depression.
iagnostic manuals exclude concerns about the etiology
f depression to arrive at a descriptive type of depressive
isorder that can be reliably diagnosed by different
nvestigators across different populations and times.
owever, if we view post-MI depression as failure to
djust to the traumatic experience of heart attack (7), its
rigin is of course qualitatively different from depression
eveloping after the loss of a loved one before MI. In the
rst case, a tailored psychological intervention would
ocus on coping with the stress of a life-threatening
xperience and, in the second, on supporting the mourn-
ng process.
de Jonge et al. (4) seem to have unraveled incident
ost-MI depression as one cardiotoxic subtype of depres-
ion. What we have not yet resolved and what ought to
uide treatment recommendations in the future are the
resumably numerous contributing factors to incident
ost-MI depression. As suggested by the authors, these are
est assumed to be both biological and psychosocial in
ature. We specifically feel that considering the effect of the
ubjective experience of an acute MI on onset of depression
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Editorial Comment December 5, 2006:2215–7fter MI could teach us another important lesson. Patients
ho perceived their heart attack as a trauma involving
hreatened death to which they responded with intense fear
r helplessness show substantial levels of post-traumatic
tress symptoms. More precisely, approximately 15% of
ost-MI patients suffer from clinical post-traumatic stress
isorder (PTSD) related to their MI (8). The diagnosis of
cute PTSD requires that for more than 1 month, patients
eexperienced the MI spontaneously in thoughts or dreams,
voided cues related to the MI such as taking cardiac
edication, and affirmed symptoms of hyperarousal such as
leeplessness and irritability (9). Post-traumatic stress dis-
rder predicted cardiovascular readmission rate in post-MI
atients (10). Symptoms of PTSD substantially overlap
ith symptoms of depression (9). However, sole treatment
f depression will only partially address PTSD-related
ymptoms and thus might not benefit cardiovascular health
n a substantial proportion of depressed post-MI patients.
Regarding accumulated anecdotal evidence from patients
ho became clinically depressed after they received beta-
drenergic receptor blocking drugs, one factor that could
voke post-MI depression is beta-blocker therapy. In a
rospective, carefully conducted case-control study also
resented in this issue of the Journal, van Melle et al. (11)
nvestigated whether beta-blocker use during hospitaliza-
ion for MI predicts the development of depressive symp-
oms and disorders during the first year post-MI. Their
ssessment of the beta-blocker regimen before MI and
uring follow-up is a strength of their study. They did not,
owever, control for previous episodes of depression, which
ould have prompted beta-blocker initiation before MI in
atients who somatize depressive affect (e.g., in the form of
alpitations and trembling) (12). In addition, their analysis
onsidered some patients who were also part of the sample
tudied by de Jonge et al. (4), but we are not told whether
eta-blocker use specifically affected symptom levels of
ncident post-MI depression at different times of follow-up.
The authors found no significant difference in any de-
ression end point between beta-blocker users and non-
sers well-matched in terms of demographic factors, base-
ine depressive symptom level, and MI severity (11).
djustment for potential confounders, including risk factors
or cardiac disease and diseases contraindicative of beta-
locker use, maintained this observation. Although support-
ng their findings, they did not discuss a previous meta-
nalysis of randomized trials of beta-blocker therapy in
ardiovascular disease—including MI—accumulating data
rom over 10,000 patients followed up for at least 6 months
13). This meta-analysis showed that overall frequency of
epressive symptoms was the same in the beta-blocker and
lacebo groups and that depressive symptom frequency did
ot relate differently to either lipophilic or hydrophilic
eta-blocking compounds (13).
Beta-blocker therapy belongs to the current guidelines
or the management of patients with acute MI and
educes mortality of post-MI patients by approximately0% (13). In spite of this evidence, beta-blockers are
nderused in secondary prevention of MI even though
ost-MI patients with diseases contraindicative for these
rugs have clear cardiovascular benefits from carefully
onitored beta-blockade (14). Correctly, van Melle et al.
11) state that no population-based study is able to
iscount individual susceptibility to a depressogenic effect
f beta-blockers. Specifically, their study cannot rule out
he possibility that post-MI patients taking high-dose
eta-blockade might become depressed with a delay of at
east half a year after their MI, thereby calling for close
onitoring of depressed mood in this particular group of
atients. Nevertheless, we agree that the most important
esson to be learned from their study is to abandon the
eneral reluctance in prescribing beta-blockers to
ost-MI patients who are depressed and do not have any
bsolute contraindication for this medication.
We conclude with a comment aimed at integrating
mportant aspects of the 2 studies discussed here (4,11).
arly in the course of an acute psychological trauma,
herapy with propranolol recently prevented storing of
raumatic memories in the brain by blocking neurotrans-
ission (15). We feel tempted to encourage an extension of
his mesmerizing avenue of research to MI populations. We
ypothesize that beta-blocker therapy might similarly ben-
fit patients who experience their heart attack as particularly
raumatic, thereby perhaps decreasing onset of incident
ost-MI depression and related cardiovascular risk.
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